Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03127514 · ClinicalTrials.gov registry record · Phase 2
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study, sponsored by Amylyx Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
NCT03127514 is a Phase 2 study that has completed, run by Amylyx Pharmaceuticals. The registered enrollment target is 137 participants.
The verdict
NCT03127514, a Phase 2 study, has completed, sponsored by Amylyx Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
Study Summary
The CENTAUR trial was a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.
Interventions
- OTHER Placebo
- DRUG AMX0035
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2017-06-22 |
| Est. Completion | 2019-11-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03127514
The ClinicalTrials.gov registry entry for NCT03127514 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amylyx Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03127514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03127514 about?
NCT03127514 is a clinical study titled "AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)". The CENTAUR trial was a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.
What is the current status of trial NCT03127514?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2017-06-22. Estimated completion is 2019-11-24.
What interventions are being tested in trial NCT03127514?
The interventions under investigation include: Placebo (OTHER), AMX0035 (DRUG).
Who is sponsoring clinical trial NCT03127514?
This trial is sponsored by Amylyx Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.